NVS · Novartis AG ADR
United States · RS rating 82 · As of 2026-11-03
| Price | 159.26 USD |
|---|---|
| 1-day change | -1.4% |
| RS rating (overall / 1M / 3M / 12M) | 82 / 86 / 73 / 77 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 36 / 36 / 29 |
| Industry group (rank) | Medical-Ethical Drugs (94) |
| EPS growth Q/Q | -38.1% |
| Sales growth Q/Q | -3.5% |
| Distance from 52-week high | +5.5% |
| Market cap (USD) | $284.7B |